Sudeep Pharma IPO
Historical offer record. This offer is closed for applications. Prices and subscriptions describe the past offer; GMP observations are unofficial past records, not current quotes or listing predictions.
Data provider: FinAPI. This is a third-party summary, not an official prospectus. Read our data limitations and editorial policy.
No GMP observations are available for this historical offer record. No premium or listing-gain estimate is shown.
Price band
₹563 – ₹593
Lot size
25 shares
Offer application amount
₹14,825
Issue size
₹895 Cr
Historical offer amount for 1 lot at the upper issue price. Confirm the lot size and application terms in the issuer prospectus.
Reported IPO schedule
| Open date | 21 Nov 2025 |
| Close date | 25 Nov 2025 |
| Allotment finalisation | 26 Nov 2025 |
| Refund initiation | 27 Nov 2025 |
| Shares credited to demat | 27 Nov 2025 |
| Reported listing date | 28 Nov 2025 |
Issue size
About Sudeep Pharma
Sudeep Pharma Limited, founded in 1989, is one of the leading manufacturers of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries. They aim to support the global healthcare ecosystem by serving their product to over 100 countries and supplying more than 200 products. To support innovation in their work, they use their own in-house technologies for encapsulation, spray drying, granulation, trituration, liposomal preparations, and mixing.
Company summary supplied by FinAPI. Read the prospectus for the issuer's disclosures and audited financials.
Use of proceeds
| Capital expenditure towards procurement of machinery for the production line located at Nandesari Facility I | 75.81 |
Offer documents and primary references
Read the issuer's offer document and any corrigenda for the full disclosures. A third-party details page is a summary; SEBI filing access does not imply an endorsement of the offer or this website.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.